Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Patents for C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
12/2003
12/17/2003EP1370255A2 Cdc25 phosphatase inhibitors
12/17/2003EP1109805B1 Inhibitors of bacterial nad synthetase
12/17/2003EP1000047B1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring
12/17/2003CN1462268A Substituted cinnamic acid guanidides, method for the production thereof, their use as medicament, and medicine containing these compounds
12/17/2003CN1131229C Salt of naphthyridine carboxylic acid derivative
12/17/2003CN1131222C Benzamide derivs and their use as APOB-100 secretion inhibitors
12/17/2003CN1131221C Drug dependence remedies
12/17/2003CN1131220C Process for one-stage catalysis synthesing N-alkyl cyclomine from hexanolactam
12/17/2003CN1131212C Phenyl-and pyridinyl derivatives
12/16/2003US6664394 As inactivator of antigen- specific T cells is useful in the prophylaxis or therapy of autoimmune diseases, disorders involving an autoimmune component or neoplastic diseases
12/16/2003US6664272 Such as 1,5-Bis-(2, 4-difluorophenyl)penta-1,4-diene-3 -one; administering to inhibit tissue factor and vascular endothelial growth factor (VEGF) production in cancerous tissue
12/16/2003US6664259 Il-8 receptor antagonists
12/16/2003US6664258 Spirocyclic dopamine receptor subtype ligands
12/16/2003CA2195125C Difluorostatone antiviral agents
12/11/2003WO2003102202A2 Process for preparing vinylaromatic compounds
12/11/2003WO2003101974A1 Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant
12/11/2003WO2003101935A1 Monomer compound comprising several cationic groups, process for making the same, and polymers comprising units deriving therefrom
12/11/2003WO2003101931A2 Preparation of 4-(n, n-disubstitutedamino) butyraldehyde acetals
12/11/2003WO2003101927A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
12/11/2003WO2003057666A3 Inhibitors of dipeptidyl peptidase iv
12/11/2003WO2002083067A3 Prodrugs via acylation with cinnamate
12/11/2003WO2002062778A3 Anti-thrombotic compounds, production and use thereof as medicaments
12/11/2003WO1999065855A3 Combinatorial libraries of geminally substituted amines
12/11/2003US20030229121 Antihistamines, antiallergens, skin disorders, antiinflammatory agents
12/11/2003US20030229094 Acetamides and benzamides that are useful in treating sexual dysfunction
12/11/2003US20030229072 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binning agents
12/11/2003US20030229050 Insecticidal anthranilamides
12/11/2003US20030228986 Polyol ester derivatives of polyamines and use in turbine oils to improve cleanliness
12/11/2003US20030228978 Catalysts containing per-ortho aryl substituted aryl or heteroaryl substituted nitrogen donors
12/11/2003CA2487957A1 An improved process for the preparation of 4-(n, n-disubstitutedamino) butyraldehyde acetals
12/11/2003CA2486803A1 Process for preparing vinylaromatic compounds
12/10/2003EP1368325A1 New asymmetric process for the preparation of diarylmethylpiperazines derivatives and novel asymmetric diarylmetylamines as intermediates
12/10/2003EP1368299A2 Substituted c-cyclohexylmethylamine derivatives
12/10/2003EP1083889B1 Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
12/10/2003EP0971885B1 Process for preparing indane-like compounds
12/10/2003EP0970046B1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
12/10/2003EP0933346B1 NOVEL p-TERPHENYL COMPOUNDS
12/10/2003CN1130403C In situ block copolymer formation during polymerization of vinyl axomatic monomer
12/09/2003US6660859 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases
12/09/2003US6660751 Sulfonamide derivatives as 5-HT7 receptor antagonists
12/09/2003US6660739 Heterocyclic amides as inhibitors of factor Xa
12/09/2003US6660466 Reacting reactive appendage compounds such as meta benzylic compounds or alpha-amide compounds with scaffold molecules having reactive functionalities and contacting the intermediate library with a reducing agent
12/09/2003CA2269394C A process for the preparation of esters of [2-[4-[(4-clorophenyl)phenylmethyl]-1-piperazinyl]-ethoxy]acetic acid
12/09/2003CA2264985C 6,8-dimercarptooctanoic acid derivatives substituted in 6-s and/or 8-s by the radical (3-methylthiopropanoyl) and pharmaceutical compositions used to treat cancerous tumors
12/04/2003WO2003099819A2 Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
12/04/2003WO2003099776A1 Calcium receptor modulating arylalkylamines
12/04/2003WO2003099769A1 Anilino liver x-receptor modulators
12/04/2003WO2003099281A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
12/04/2003WO2003099274A1 Hepatitis c virus inhibitors
12/04/2003WO2003099266A2 Acetamides and benzamides that are useful in treating sexual dysfunction
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003057169A3 4-dedimethylamino tetracycline compounds
12/04/2003WO2003034989A3 α-HYDROXYARYLBUTANAMINE INHIBITORS OF ASPARTYL PROTEASE
12/04/2003WO2003024946A3 Oxamate derivatives containing a variously substituted nitrogen heterocycle
12/04/2003WO2003020686A3 Method for producing 4-amino-1-naphthol ethers
12/04/2003US20030225302 Aromatic amides, their preparation process and their use as pesticides
12/04/2003US20030225285 Oxidizing a protected aminoalcohol to a chiral protected aminoaldehyde and diastereoselectively forming the aminoepoxide from said aminoaldehyde with an organometallic methylene-adding reagent in an appropriate solvent
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225228 A catalyst for the polymerization of olefins, contains a titanium zirconium or hafnium complex of a dianionic bidentate ligand, (at least one of donor atoms of the ligand is a nitrogen atom substituted by a pyrrolyl group)
12/04/2003US20030225179 Carbocyclic oxo, amines used as photoinitiators, formed by reacting 1-(4-(bis-(2-hydroxyethyl)-amino))-2-methyl-2-morpholino-1-propanone with caprolactone in the presence of catalysts; inks
12/04/2003US20030225158 Compounds that modulate PPAR activity and methods for their preparation
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225130 Triphenylalkene derivatives and their use as selective estrogen receptor modulators
12/04/2003US20030225086 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
12/04/2003US20030225084 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others.
12/04/2003US20030225076 Mitogen ERK Kinase ("MEK") enzyme inhibitors
12/04/2003US20030225071 N-heterocyclic amides and carbamates
12/04/2003US20030225065 Use of 4-(1,4-diazepan-1-yl)- or 4-piperazin-1-yl-2-aminophenyl phenyl sulfones for treatment of disorders of the central nervous system.
12/04/2003US20030225059 Cyclohexyl derivatives and their use as therapeutic agents
12/04/2003US20030224940 Alpha-sulfin-and alpha-sulfonamino acid amide derivatives
12/04/2003CA2486644A1 Anilino liver x-receptor modulators
12/04/2003CA2486564A1 Acetamides and benzamides that are useful in treating sexual dysfunction
12/03/2003EP1366030A2 Melanin concentrating hormone receptor ligands
12/03/2003EP1366018A1 Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
12/03/2003EP1366015A1 Benzene-1 2-diol mannich bases ligands polymers and method of selective metal ions removal
12/03/2003EP1366010A2 Method for producing vinyl, aryl and heteroaryl acetic acids and derivatives thereof
12/03/2003EP1178953B1 Aromatic amides
12/03/2003CN1460101A Novel compounds inhibiting factor Xa activity
12/03/2003CN1460097A NF-kB inhibitor containing substituted benzoic acid derivative as active ingredient
12/03/2003CN1129581C Cyanophenyl derivatives
12/02/2003US6656971 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions
12/02/2003US6656965 HIV protease inhibitors based on amino acid derivatives
12/02/2003US6656954 Such as N-hydroxy-2-(((4-phenoxyphenyl)-sulfonyl)methyl) benzamide which inhibits matrix metalloprotease activity
12/02/2003US6656943 1-phenyl-4-benzlpiperazines: dopamine receptor subtype specific ligands
12/02/2003US6656737 Reacting 9-anthracenemethanol, pyridine, and p-nitrophenyl chloroformate; reacting the product with an amine, especially piperazine, to form a product that can be used to determine the total amount of isocyanate in a sample
12/02/2003US6656498 Cationic liposomes for gene transfer
12/02/2003CA2244785C Pentafluorobenzenesulfonamides and analogs
11/2003
11/27/2003WO2003097623A1 Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent
11/27/2003WO2003097589A1 Method for the production of sulphamic acid halogenides
11/27/2003WO2003097576A2 Diamino-functional chalcones
11/27/2003WO2003097575A2 Amino-functional chalcones
11/27/2003WO2003097574A2 Aminoalkoxy-functional chalcones
11/27/2003WO2003096989A2 Anti tubercular drug: compositions and methods
11/27/2003WO2003014064A8 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
11/27/2003WO2003009850A1 Substituted piperazines as modulators of the melanocortin receptor
11/27/2003WO2002100813A3 Modulators of peroxisome proliferator activated receptors
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003US20030220496 3-(optionally hydroxyl)-4-(cyclopropylcarbonyl)-cumene intermediate
11/27/2003US20030220493 Selectively inhibit binding to the alpha -1a adrenergic receptor; chemical intermediates
1 ... 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 ... 341